Stoke Therapeutics (STOK) Change in Acquisitions & Divestments (2022 - 2026)

Stoke Therapeutics has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $60.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 85.67% year-over-year to $60.9 million; the trailing twelve-month figure through Mar 2026 stood at $164.7 million (up 98.89% YoY), and the FY2025 full-year result was $136.6 million, up 127.63% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $60.9 million, up from $37.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $79.0 million in Q3 2022, with the low at $9.0 million in Q1 2022.
• Average Change in Acquisitions & Divestments over 5 years is $32.8 million, with a median of $31.4 million recorded in 2024.
• Year-over-year, Change in Acquisitions & Divestments jumped 491.67% in 2023 and sank 81.22% in 2024.
• Tracing STOK's Change in Acquisitions & Divestments over 5 years: stood at $18.0 million in 2022, then decreased by 16.8% to $15.0 million in 2023, then jumped by 100.0% to $30.0 million in 2024, then increased by 24.66% to $37.4 million in 2025, then surged by 62.84% to $60.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $60.9 million (Q1 2026), $37.4 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.

Peer Comparison